The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to Siemens Healthineers for CLINITEST Rapid COVID-19 Antigen Self-Test.
The receipt of EUA will enable Siemens Healthineers to make the at-home or over-the-counter self-test available countrywide from January.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Claimed to be easy to use, this nasal swab test helps in the quick detection of SARS-CoV-2 and offers test results in 15 minutes.
The CLINITEST Rapid COVID-19 Antigen Self-Test has been authorised for self-testing use by people from the age of 14 years and above or adult-collected samples from individuals between the age of two and 13 years.
Siemens Healthineers stated that it has secured the production capacity for the test kit in the tens of millions in a month.
Siemens Healthineers Point of Care Diagnostics head Christoph Pedain said: “Undetected Covid-19 exposure is a major driver of community spread. With the
CLINITEST Rapid COVID-19 Antigen Self-Test, consumers will have access to a fast, reliable, and convenient test to provide additional safety.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Siemens Healthineers is proud to bring this high-quality test, already used and trusted by families, medical professionals, businesses and governments in many parts of the world, to the United States under FDA Emergency Use Authorization.”
The test kit has been analysed in a study designed for the US market and completely conducted in the US with laypersons, and therefore covers the presently circulating variants of concern of SARS-CoV-2.
It has a sensitivity of 86.5% and a specificity of 99.3% as against the nucleic acid (PCR) detection method.
This clinical data has been established under the company’s participation in the National Institutes of Health’s (NIH) Rapid Acceleration of Diagnostics’ (RADx) Independent Test Assessment Programme (ITAP).
